These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15955898)

  • 1. Objective response rate as a surrogate end point: a commentary.
    Fleming TR
    J Clin Oncol; 2005 Aug; 23(22):4845-6. PubMed ID: 15955898
    [No Abstract]   [Full Text] [Related]  

  • 2. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
    Bruzzi P; Del Mastro L; Sormani MP; Bastholt L; Danova M; Focan C; Fountzilas G; Paul J; Rosso R; Venturini M
    J Clin Oncol; 2005 Aug; 23(22):5117-25. PubMed ID: 15955906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
    Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
    J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
    Piedbois P; Buyse M
    Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.
    Huber KE; Carey LA; Wazer DE
    Semin Radiat Oncol; 2009 Oct; 19(4):204-10. PubMed ID: 19732684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy.
    Andreopoulou E; Hortobagyi GN
    J Clin Oncol; 2008 Aug; 26(22):3660-2. PubMed ID: 18669447
    [No Abstract]   [Full Text] [Related]  

  • 12. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
    Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
    J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
    [No Abstract]   [Full Text] [Related]  

  • 13. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them?
    Bear HD
    J Clin Oncol; 2008 Mar; 26(8):1195-7. PubMed ID: 18323543
    [No Abstract]   [Full Text] [Related]  

  • 15. Cerebrospinal fluid tumor marker levels in predicting response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.
    Kosmas C; Tsavaris NB; Tsakonas G; Soukouli G; Gassiamis A; Mylonakis N; Karabelis A
    Med Sci Monit; 2005 Aug; 11(8):CR398-401. PubMed ID: 16049383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Dickler M
    Nat Clin Pract Oncol; 2005 Oct; 2(10):498-9. PubMed ID: 16205767
    [No Abstract]   [Full Text] [Related]  

  • 17. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
    Mohsin SK; Allred DC; Osborne CK; Cruz A; Otto P; Chew H; Clark GM; Elledge RM
    Breast Cancer Res Treat; 2005 Dec; 94(3):205-11. PubMed ID: 16267611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill S; Sargent D
    Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases.
    Carter MR; Hornick JL; Lester S; Fletcher CD
    Am J Surg Pathol; 2006 Mar; 30(3):300-9. PubMed ID: 16538049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.